Evoke Pharma (DB:EV0) - Stock Price, News & Analysis

EV0 Stock Overview

A specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. More details

EV0 fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	5/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Earnings are forecast to grow 117.22% per year

Earnings have grown 5% per year over the past 5 years

Trading at good value compared to peers and industry

Risk Analysis

Shareholders have been substantially diluted in the past year

Does not have a meaningful market cap (€6M)

Shares are highly illiquid

Evoke Pharma, Inc. Competitors

Biofrontera

XTRA:B8FK

€15.8m

MPH Health Care

DB:93M1

€102.8m

SynBiotic

DUSE:SBX

€27.9m

Redx Pharma

DB:0RX

€65.0m

Price History & Performance

Summary of all time highs, changes and price drops for Evoke Pharma
Historical stock prices
Current Share Price	US$3.97
52 Week High	US$15.00
52 Week Low	US$0.33
Beta	0.38
11 Month Change	0%
3 Month Change	-2.71%
1 Year Change	-70.46%
33 Year Change	-97.46%
5 Year Change	-96.68%
Change since IPO	-99.69%

Recent updates

Shareholder Returns

	EV0	DE Pharmaceuticals	DE Market
7D	0%	-0.3%	0.8%
1Y	-70.5%	-18.3%	8.6%

Return vs Industry: EV0 underperformed the German Pharmaceuticals industry which returned -6.7% over the past year.

Return vs Market: EV0 underperformed the German Market which returned 19.6% over the past year.

Price Volatility

Is EV0's price volatile compared to industry and market?
EV0 volatility
EV0 Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	6.9%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: EV0's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: Insufficient data to determine EV0's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2007	4	Matt D'Onofrio	www.evokepharma.com

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers.

Evoke Pharma, Inc. Fundamentals Summary

How do Evoke Pharma's earnings and revenue compare to its market cap?
EV0 fundamental statistics
Market cap	€5.36m
Earnings (TTM)	-€6.04m
Revenue (TTM)	€6.96m

0.8x

P/S Ratio

-0.9x

P/E Ratio

Is EV0 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
EV0 income statement (TTM)
Revenue	US$7.53m
Cost of Revenue	US$227.94k
Gross Profit	US$7.30m
Other Expenses	US$13.83m
Earnings	-US$6.53m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-7.97
Gross Margin	96.97%
Net Profit Margin	-86.75%
Debt/Equity Ratio	187.6%

How did EV0 perform over the long term?

See historical performance and comparison

EV0 Stock Overview

Rewards

Risk Analysis

Evoke Pharma, Inc. Competitors

XTRA:B8FK

€15.8m

DB:93M1

€102.8m

DUSE:SBX

€27.9m

DB:0RX

€65.0m

Price History & Performance

Recent News & Updates

Evoke Pharma, Inc. Revises Sales Guidance for the Year 2024

Evoke Pharma, Inc. Appoints Benjamin Smeal to Serve as Class II Director

Evoke Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $1.921957 million.

Second quarter 2024 earnings released: US$0.93 loss per share (vs US$6.71 loss in 2Q 2023)

Evoke Pharma, Inc. Revises Earnings Guidance for the Year 2024

Evoke Pharma, Inc. Revises Earnings Guidance for the Year 2024

Recent updates

Evoke Pharma, Inc. Revises Sales Guidance for the Year 2024

Evoke Pharma, Inc. Appoints Benjamin Smeal to Serve as Class II Director

Evoke Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $1.921957 million.

Second quarter 2024 earnings released: US$0.93 loss per share (vs US$6.71 loss in 2Q 2023)

Evoke Pharma, Inc. Revises Earnings Guidance for the Year 2024

Evoke Pharma, Inc. Revises Earnings Guidance for the Year 2024

Evoke Pharma Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price Requirement

First quarter 2024 earnings released: US$0.17 loss per share (vs US$0.67 loss in 1Q 2023)

Evoke Pharma, Inc., Annual General Meeting, May 22, 2024

Evoke Pharma, Inc. Announces Chief Executive Officer Changes as of March 31, 2024

Evoke Pharma, Inc. Provides Earnings Guidance for 2024

New major risk - Revenue and earnings growth

Evoke Pharma, Inc. to Report Q4, 2023 Results on Mar 14, 2024

Evoke Pharma Receives Letter from Nasdaq Regarding Non-Compliance with Nasdaq’s Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market Under Nasdaq Listing Rule 5550(a)(2)

New major risk - Shareholder dilution

Evoke Pharma, Inc. has completed a Follow-on Equity Offering.

Evoke Pharma Announces Update on Non-Compliance Notice from Nasdaq

Evoke Pharma Receives Notice from Nasdaq

Evoke Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $15 million.

Third quarter 2023 earnings released: US$0.51 loss per share (vs US$0.60 loss in 3Q 2022)

New major risk - Revenue and earnings growth

Evoke Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $30 million.

Evoke Pharma, Inc. Provides Summary of Real-World Data on the Positive Impact of GIMOTI

Evoke Pharma, Inc. Receives Notice of Allowance from U.S. Patent and Trademark Office for GIMOTI

Second quarter 2023 earnings released: US$0.56 loss per share (vs US$0.71 loss in 2Q 2022)

Nasdaq Grants Evoke Pharma an Extension Until November 20, 2023 to Regain Compliance

Evoke Pharma Receives Notice from Nasdaq Regarding Non-Compliance with the Minimum Stockholders’ Equity Requirement for Continued Listing on the Nasdaq Capital Market

First quarter 2023 earnings released: US$0.67 loss per share (vs US$0.80 loss in 1Q 2022)

Full year 2022 earnings released: US$2.62 loss per share (vs US$3.18 loss in FY 2021)

Evoke Pharma, Inc. Announces Executive Changes

Evoke Pharma, Inc. Announces Teva Ends Pursuit of Paragraph IV ANDA Against Gimoti

Evoke Pharma Announces Acceptance of an Abstract at the Academy of Managed Care Pharmacy (AMCP) Annual Meeting 2023

Third quarter 2022 earnings released: US$0.60 loss per share (vs US$0.73 loss in 3Q 2021)

Evoke Pharma, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Evoke Pharma, Inc. announces United States Patent and Trademark Office Issues Notice of Allowance for the its Product, GIMOTI® (Metoclopramide) Nasal Spray

Second quarter 2022 earnings released: US$0.71 loss per share (vs US$0.85 loss in 2Q 2021)

Evoke Pharma, Inc. to Report Q2, 2022 Results on Aug 10, 2022

Evoke Pharma, Inc. Expands IP Portfolio with Addition of Canadian Patent Covering GIMOTI Method of Use

Evoke Pharma Announces Approval of GIMOTI® to Florida State Medicaid Program

Evoke Pharma Regains Compliance with Nasdaq Listing Requirements and Provides Financial Update

Evoke Pharma, Inc. Announces Real-World Data Analysis Reveals Lower Risk of Tardive Dyskinesia with Metoclopramide Than Previously Reported

Evoke Pharma, Inc. Announces Positive Findings from the First Patient-Centered Survey Related to GIMOTI®

No longer forecast to breakeven

Evoke Pharma, Inc. to Report Q1, 2022 Results on May 10, 2022

Evoke Pharma Granted FDA Market Exclusivity for Gimoti®

Evoke Pharma, Inc. Announces Approval of GIMOTI to the Texas Medicaid Preferred Drug List

Insufficient new directors

No longer forecast to breakeven

Evoke Pharma, Inc. to Report Q4, 2021 Results on Mar 08, 2022

Evoke Pharma, Inc. Announces Positive Outcomes from an Additional Research Study Conducted for GIMOTI

Evoke Pharma, Inc. Announces Positive Findings from A Second Market Research Study Conducted for Gimoti® (Metoclopramide) Nasal Spray

Evoke Pharma, Inc. Announces the Launch of Wave 1 of an Innovative Social Media Campaign to Reach Patients Directly with Education About Diabetic Gastroparesis

Independent Director has left the company

No longer forecast to breakeven

Revenue misses expectations

Evoke Pharma, Inc. to Report Q4, 2020 Results on Mar 11, 2021

New 90-day low: €2.00

Evoke Pharma, Inc. has completed a Follow-on Equity Offering in the amount of $12.5 million.

Evoke Pharma, Inc. Announces, Through its Marketing Partner, Eversana Life Science Services, LLC, Conducted an ATU (Awareness, Trial, and Usage) Study, Quantitative Survey to Measure Physician Awareness, Trial, and Product Usage, for GIMOTI